Drugs & Targets Friends study: drugs that earn Breakthrough Therapy Designation at FDA provide maximum benefit in lung cancer May 27, 2022Vol.48 No.21
Trials & Tribulations Cancer is complex and dynamic—ergo, dose optimization calls for mathematical modeling May 13, 2022Vol.48 No.19By Alexander Anderson, Robert Gillies and Robert Gatenby
Conversation with The Cancer Letter FDA’s Lola Fashoyin-Aje: It’s time to increase racial diversity in trials—here’s a draft guidance for how this can be done May 06, 2022Vol.48 No.18By Matthew Bin Han Ong
Regulatory News Pazdur at FDA-ASCO workshop: Failure to optimize the dose is akin to building a house on quicksand May 06, 2022Vol.48 No.18By Alice Tracey
Guest Editorial Let’s learn from our neighbors from the North as we get the menthol flavor out of cigarettes May 06, 2022Vol.48 No.18By David Balis
Oncologists, advocates, FDA call for an end to MTD and the “more is better” era in cancer drug dosing April 29, 2022Vol.48 No.17By Alice Tracey
Regulatory News As part of Cancer Moonshot, FDA seeks to prohibit menthol cigarettes, flavored cigars April 29, 2022Vol.48 No.17By Paul Goldberg
Drugs & Targets FDA grants clearance to ClearPoint Neuro’s SmartFrame Array version 1.1 April 29, 2022Vol.48 No.17
Clinical Roundup FDA OCE commentary: Cancer burden facing Asian Americans partly caused by racism April 22, 2022Vol.48 No.16
Drugs & Targets FDA grants priority review to Enhertu in previously treated HER2-mutant metastatic NSCLC April 22, 2022Vol.48 No.16
